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Backgrounds: The process of amyloid proteins aggregation causes several human neuropathologies. In some
cases, e.g. fibrillar deposits of insulin, the problems are generated in the processes of production and purification of
protein and in the pump devices or injectable preparations for diabetics. Experimental kinetics and adequate
modelling of chemical inhibition from amyloid aggregation are of practical importance in order to study the viable
processing, formulation and storage as well as to predict and optimize the best conditions to reduce the effect of
protein nucleation.
Results: In this manuscript, experimental data of insulin, Aβ42 amyloid protein and apomyoglobin fibrillation from
recent bibliography were selected to evaluate the capability of a bivariate sigmoid equation to model them. The
mathematical functions (logistic combined with Weibull equation) were used in reparameterized form and the
effect of inhibitor concentrations on kinetic parameters from logistic equation were perfectly defined and
explained. The surfaces of data were accurately described by proposed model and the presented analysis
characterized the inhibitory influence on the protein aggregation by several chemicals. Discrimination between true
and apparent inhibitors was also confirmed by the bivariate equation. EGCG for insulin (working at pH = 7.4/T = 37°C)
and taiwaniaflavone for Aβ42 were the compounds studied that shown the greatest inhibition capacity.
Conclusions: An accurate, simple and effective model to investigate the inhibition of chemicals on amyloid protein
aggregation has been developed. The equation could be useful for the clear quantification of inhibitor potential of
chemicals and rigorous comparison among them.
Keywords: Protein fibrillation kinetics, Mathematical modeling, Sigmoid bivariate equationBackground
The aggregation and fibrillation of proteins has been com-
monly associated with numerous degenerative disorders
in humans including Alzheimer’s, Parkinson’s, prion’s,
diabetes type II and Huntington’s diseases [1-5]. These
proteins, called amylodogenics, are also involved in pro-
duction, purification and formulation interferences of
biotechnology and pharmacologic processes [6,7]. The
phenomenon of protein aggregation, led by nucleation-
dependent polymerization mechanism, consists in the
formation of amyloid fibrils formulated with β-sheet
structures in cross-β-sheet arrangement producing in-
soluble aggregates [8-10]. For example, insulin peptide
also generates fibrillar structures under specific conditions
such as low pH, high temperatures or organic solventsCorrespondence: jvazquez@iim.csic.es
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reproduction in any medium, provided the ordilution [11-13]. Those phase transformations are not
observed in vivo but are very common, for example, in
the clinical preparations of insulin for diabetics [14].
Human amyloid proteins (Aβ) are peptides of rather 39-
42 residues. Aβ40 contains 40 amino acids and Aβ42 is
the major isoform in the Aβ peptides with 42 residues
polypeptide chain and it is the responsible of amyloid
plaques generated in Alzheimer’s disorder [15,16].
In general, much of the success in the future application
of chemicals to inhibit the in vivo formation of such fibrils
is dependent on the correct modelling and evaluation of
in vitro kinetic data in order to establish protocols of ac-
tion, effectiveness of molecules and dose-optimization of
compounds. The kinetic description of amyloid protein
aggregation based on mechanistic and thermodynamic ap-
proaches have been extensively studied [17-22] and an
ample number of plausible mechanisms of nucleation and
fibrillation have been proposed [23,24]. So remarkable,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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listic and Crystallization-like Model, have been recently
developed. Both have solid biophysical basis and they were
successfully applied to describe and explain the ex-
perimental data of different amyloid protein aggrega-
tion [25-28]. However, the combined effect of anti-
aggregation protein agents, e.g. surfactants, osmolytes and
food additives, on time-dependent responses has not been
modelled by that way or by means of empirical equations.
Although the use of empirical sigmoid equations,
mainly the logistic equation, does not provide a direct
explanation of the molecular steps that underlie in the
generation of fibrils, it is a robust tool to examine pro-
tein aggregation kinetic data and to address all the
phases of the process [4,29,30]. In addition, other au-
thors assimilated the parameters from logistic [20] to
those obtained by an autocatalytic mechanism [23,27].
Nonetheless, that equation is always formulated with-
out the parameters (fibrillation rate and lag phase) in
an explicit form hindering the estimation of their stat-
istical error.
In the present work, the capability of fit and experi-
mental data predictability of a sigmoid bivariate model
that simulates the growth of aggregation process on dif-
ferent proteins along with the effects of inhibitory che-
micals on the kinetic parameters is explored in selected
cases obtained from the literature. The results reveal its
efficacy and validity to analyze the most relevant param-
eters that describe geometrically and macroscopically
the mentioned process.
Methods
Experimental data
Amyloid protein aggregation data were collected from
results previously reported in the bibliography and digi-
tized from the published curves using GetData Graph
Digitizer 2.24. The kinetics of insulin inhibition induced
by (−)-epigallocatechin-3-gallate (EGCG) were selected
from Wang et al. [31], methylglyoxal effects were col-
lected from Oliveira et al. [32] and those produced by
1,2-diheptanoyl-sn-glycero-3-phosphocholine (di-C7-PC)
were described in Wang et al. [33]. Two conditions of
EGCG affecting to fibrillation kinetics were used: EGCG_1
(case 1) studied at pH = 2.0/T = 60°C and EGCG_2 (case
2) at pH = 7.4/T = 37°C.
On the other hand, the aggregation kinetics of Aβ42
amyloid protein inhibited by apigenin and taiwaniafla-
vone were selected from Thapa et al. [16] and the data af-
fected by ectoine and hydroxyectoine from Kanapathipillai
et al. [15]. Finally, apomyoglobin fibrillation expe-
riments were published in Vilasi et al. [34]. The data-
sets were obtained by the two most common methods
used to probe amyloid formation in vitro, the incre-
ment in light scattering of the protein solution due toinsolubilization, and the increase in ThT fluorescence due
to amyloid binding.
Mathematical modelling
The model developed to simulate the process of aggrega-
tion and hence insulin fibrillation was defined by a bivari-
ate equation. Such model is based on the combination of
Weibull function as chemical-concentration model [35,36]
modifying the most important parameters of the repara-
meterized logistic equation [37] used for aggregation de-
scription. This expression (1) has been successfully used,
in recent works, to evaluate the inhibitory effect of organic
acids and heavy metals on the growth of various bacteria
[38,39]. Its mathematical form is as follows (see also
Appendix section):
X ¼ Xm•
1þ exp 2þ 4vm•Xm• λ•−tð Þ
h i ; where : ð1Þ
Xm• ¼ Xm 1−Kx 1− exp − ln2 Cmx
 ax   
vm• ¼ vm 1−Kv 1− exp − ln2 Cmv
 av   
λ• ¼ λ 1þ Kλ 1− exp − ln2 Cmλ
 aλ   
where, vm is the maximum aggregation rate, Xm is the
maximum aggregation growth, λ is the lag phase and C
is the chemical concentration. The meanings of other
symbolic notations as well as the corresponding units
are summarized in Table 1. In the experimental data
chosen, the dependent variable of response or time-
dependent signals (X) to detect amyloid protein aggrega-
tion were absorbance at 600 nm (data obtained from
Wang et al. [31]), relative ThT fluorescence intensity (%)
(data from Wang et al. [33]) and ThT fluorescence inten-
sity at 482 nm or 490 nm (data obtained from Thapa
et al. [16]; Kanapathipillaia et al. [15]; Oliveira et al. [32]
and Vilasi et al. [34]).
Additionally, a global parameter (EC50,τ) was also se-
lected for the overall description of chemical effects on
fibrillation growth studies according the algebraic steps
previously described [38]. This parameter was defined as
the chemical concentration (in mM) that reduces the ag-
gregation by 50% compared to that produced by the
control without agent at time (τ) which also reduces the
maximum aggregation by 50%.
Numerical methods and statistical analysis
The fitting procedures and parametric estimates from
the experimental results were performed by minimizing
the sum of quadratic differences between the observed
and model-predicted values using the nonlinear least-
Table 1 Symbolic notations used and corresponding units
Insulin aggregation kinetics measured by
absorbance or fluorescence
X : Amyloid aggregation growth measured as absorbance at 600 nm, relative ThT fluorescence intensity
(%) and ThT fluorescence intensity at 482 nm or 490 nm. Units: absorbance units (AU) or (%).
t : Time. Units: h or d
Xm : Maximum aggregation growth. Units: AU or %
vm : Maximum aggregation rate. Units: AU h
−1, AU d−1 or % h−1
λ : Lag phase. Units: h or d
Xm• : Maximum insulin aggregation affected by chemical agent. Units: AU or %
vm• : Maximum insulin aggregation rate affected by chemical agent. Units: AU h
−1, AU d−1 or % h−1
λ• : Lag phase affected by chemical agent. Units: h or d
Concentration effects on insulin aggregation kinetics
C : Concentration of chemical agent. Units: mM or μM
Kx : Maximum response affecting on Xm. Dimensionless
mx : Concentration corresponding to the semi-maximum response affecting on Xm. Units: mM or μM
ax : Shape parameter affecting on Xm. Dimensionless
Kv : Maximum response affecting on vm. Dimensionless
mv : Concentration corresponding to the semi-maximum response affecting on vm. Units: mM or μM
av : Shape parameter affecting on vm. Dimensionless
Kλ : Maximum response affecting on λ. Dimensionless
mλ : Concentration corresponding to the semi-maximum response affecting on λ. Units: mM or μM
aλ : Shape parameter affecting on λ. Dimensionless
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macro from Microsoft Excel spreadsheet. The confi-
dence intervals of the best-fit values for the parametric
estimates (Student’s t test, α = 0.05), consistency of the
mathematical models (Fisher’s F test; p < 0.05) and covari-
ance and correlation matrices were calculated using the
‘SolverAid’ macro, which is freely available from Levie’s
Excellaneous website http://www.bowdoin.edu/~rdelevie/
exellaneous/. An example of the type of Excel spreadsheet
used for modeling (Ab42amyloid apigenin case) was pro-
vided as Additional file 1. These statistical procedures and
residual analysis (Durbin-Watson test) were confirmed
and evaluated, respectively, by DataFit 9 (Oakdale Engi-
neering, Oakdale, PA). Moreover, bias and accuracy fac-
tors of fittings (Bf and Af, respectively) were calculated
according to the expressions reported by Ross [40].
Results and discussion
Characteristics and simulations of bivariate model
In the description of amyloidogenic fibrillation growths,
the logistic equation used to formalize their kinetic pro-
files is always formulated through an explicit expression
based on the time required to reach 50% of the maximal
aggregation (x0) and a time parameter (τ), although the
initial lag phase and the aggregation rate are commonly the
most important parameters that need to be calculated [30].
In this work, the logistic equation was reparameterized tomake the lag phase (λ) and the maximum aggregation rate
(vm), which represents the overall aggregation process rate,
explicit (Figure 1). This last coefficient more adequately
characterizes the reaction rate of fibrillation than the par-
ameter conventionally used (kapp, defined as specific or ap-
parent rate) because it is less sensitive to experimental
error and because it is a more efficient to describe the glo-
bal rate of the kinetic process [41]. Additionally, the vm cal-
culated from the experimental data obtained by Sabaté
et al. [42] for yeast prion proteins follows the Arrhenius de-
pendence with temperature (data not shown).
In contrast, the fit using the reparameterized functions
can be used to easily calculate the confidence intervals
of the parameters. The algebraic steps required to obtain
the corresponding reparameterization of λ and vm from
the logistic equation are detailed in the Appendix.
Thus, the parameters from this equation define all of the
aggregation kinetic phases [19]: pre-nucleation, which is
characterized by λ, post-nucleation, which is represented
by vm or τ, and elongation, which is determined by Xm.
The absolute correlation between the lag phase and the
aggregation growth was recently demonstrated in several
sets of protein data [43]. Indeed, this relationship is obvi-
ous because the specific or apparent rate (kapp or kg, de-
pending on the authors) is inversely proportional to the
lag phase based the following expression when the logistic
model (1) is applied [44]:
Figure 1 Left, Graphical description of the kinetic parameters (Xm, λ, vm and τ) from the logistic equation (A.8) and the corresponding
aggregation phases: pre-nucleation, post-nucleation and elongation. Right, Simulations of the most common profiles for the parameters
(Xm•, λ•, vm•), affected by chemical concentration, using the Weibull equations (A.15).
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Figure 2 shows an illustrative set of simulations that
were developed under the numerical conditions de-
scribed in Table 2. In these simulations, all of the pos-
sible sigmoid effects of the chemical concentration on
the logistic parameters are defined. Weibull’s equation,
which was adequately configured to simulate the dose-
response trends, is a mathematical tool that provides ex-
cellent predictions for varied experimental profiles from
different scientific fields [45,46]. In the present con-
text, the flexibility of this equation to describe different
chemical-concentration relationships as linear, sigmoid,
exponential, or hyperbolic curves depending on the nu-
merical values of the parameters is particularly valuable.
The combination of both of these mathematical resources
(1) generates a wide variety of theoretical casuistries
that will be verified using the experimental data se-
lected below.
Inhibitory effect of EGCG on insulin aggregation
The representation of the experimental data from se-
lected cases and surfaces predicted by equation (1) are
depicted in Figure 3A and B. The results of the param-
eter estimations and the statistical analysis of the fit for
the EGCG influence on insulin fibrillation are summa-
rized in Table 3. Both datasets were accurately fitted
with equation (1) to obtain R2adj values greater than 0.98.
Moreover, the p-values obtained from Fisher’s F test in-
dicated the complete consistency and robustness of the
equation to the adjustment of the experimental patterns.
The residual analysis through the Durbin-Watson test
revealed a lack of residual autocorrelation and therefore
a random distribution (data not shown).At an acidic pH and a high temperature, the effect of
EGCG on the kinetic parameters was not significant for
the maximum aggregation rate but statistically signifi-
cant for Xm and the lag phase. As can be observed in
Figure 3A, the slopes of the sigmoid curves were parallel
to the influence of the EGCG concentration, and the
surface can be assimilated to that simulated in Figure 2D
but with less effect on Xm. These results show a longer
pre-nucleation phase, which indicates that EGCG blocks
the formation of the seeding nuclei without changing
the fibril elongation rate (post-nucleation). This behav-
iour is consistent with the definition reported by Martins
[26] who denominates the compounds that modify kin-
etic parameters (for instance in the present case, vm and/
or λ) as true inhibitors.
In contrast, different surface and parametric responses
were observed for EGCG_2 up to a concentration of 0.2
mM polyphenol with only significant modifications in
the maximum aggregation growth parameter (Figure 3B).
Under experimental conditions of higher pH and lower
T, EGCG acts as an apparent inhibitor that only alters
the thermodynamic properties of aggregation process
[26]. Higher concentrations of EGCG (from 0.35 to 0.7
mM) led to an increase in the fibrillation response more
than the inhibition of the amyloid process [31]. These
experimental points were deleted in this mathematical
analysis because biphasic aggregation data with profiles
of decreasing and increasing values of Xm cannot be
fitted by the proposed equation or by any other simple
equation.
The global description of chemical inhibition was cal-
culated by means of a single index: EC50,τ (Table 3). This
parameter can be defined as a summary of all of the ef-
fects on the aggregation kinetics observed at the time re-
quired to reach the semi-maximum aggregation growth.
Thus, the obtained value of this parameter can be used
Figure 2 Profiles obtained by simulation under the numerical conditions specified in Table 2 using the equation (1) and that
representing all the theoretical kinetics of protein aggregation process. A: all the parameters from logistic equation (Xm, vm and λ) are
affected by chemical concentration; B: parameters (Xm and vm) are modified by chemical; C: only the parameter Xm is affected by chemical;
D: parameters (Xm and λ) are modified by chemical; E: parameters (vm and λ) are affected by chemical; F: only the parameter vm is modified by
chemical; G: only the parameter λ is affected by chemical. In all cases, time (t), aggregation response (X) and chemical concentration (C) are
simulated with arbitrary units.
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of chemicals to reduce the protein fibrillation. The results
demonstrated that the most inhibitory conditions for
EGCG are established at neutral pH and a lower tem-
perature (case 2), but these conditions require a longer
time (τ) to achieve the parameter EC50,τ.
Inhibitory effect of di-C7-PC and methylglyoxal on insulin
aggregation
Figure 3C displays the surface described by equation (1)
and data on the insulin kinetics in the presence of asurfactant. The parameter values and the statistical char-
acteristics of the modeling were also determined (Table 3).
All of the statistical results revealed good agreement and
accuracy between the observed and the predicted values,
the consistency of the equation, and a lack of bias during
the fitting process.
Regarding the effects, the two kinetic parameters vm and
Xm were significantly affected by di-C7-PC, whereas the
lag phase was not modified by the surfactant (Student’s t
test, α = 0.05), as determined in the simulated conditions
defined by Figure 2B. This result is in agreement with data
Table 2 Arbitrary numerical values defined for the
simulations of Figure 1 (A, B, C, D, E, F and G) according
to the parameters defined in the equation (1)
Simulation conditions
Parameters A B C D E F G
Aggregation growth Xm 1.00 1.00 1.00 1.00 1.00 1.00 1.00
vm 0.25 0.25 0.25 0.25 0.50 0.20 0.50
λ 3.00 3.00 3.00 3.00 4.00 5.00 4.00
Effect on Xm Kx 1.00 1.00 1.00 1.00 - - -
mx 5.00 5.00 5.00 5.00 - - -
ax 2.00 2.00 2.00 2.00 - - -
Effect on vm Kv 1.00 1.00 - - 0.60 0.60 -
mv 4.00 4.00 - - 3.00 8.00 -
av 2.00 2.00 - - 2.00 2.00 -
Effect on λ Kλ 1.00 - - 1.00 4.00 - 4.00
mλ 2.00 - - 2.00 10.00 - 10.00
aλ 2.00 - - 2.00 2.00 - 2.00
Figure 3 Insulin fibrillation kinetics at different concentrations of EGC
(1) (surface). X: aggregation data measured by absorbance at 600 nm (AU
intensity (%). A: experimental data of EGCG obtained at pH = 2.0 and T = 60
C: di-C7-PC data. D: methylglyoxal data.
Vázquez BMC Pharmacology and Toxicology 2014, 15:9 Page 6 of 11
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copper/β-amyloid [47] or glutathione/hen egg-white lyso-
zyme, although these data were obtained using a non-
mathematical approach [48]. The value of EC50,τ was simi-
lar to that obtained for EGCG (case 1) for a lower initial
concentration of insulin, but a much longer time was re-
quired to obtain this parametric value (150.68 h).
Similar inhibitory responses were also observed with
methylglyoxal; thus, vm and Xm were the kinetic parame-
ters inhibited by this aldehyde form of pyruvic acid
(Table 3 and Figure 3D). Under an initial insulin concen-
tration (3 g/L) that was higher than the initial EGCG
concentration, methylglyoxal effectively reduced the ag-
gregation growth (0.33 mM) within a shorter time (3.9
h). Both chemicals (di-C7-PC and methylglyoxal), under
the experimental conditions assayed, showed similar fea-
tures of true inhibitors [26]. The application of the pro-
posed methodology may help the design of optimal
strategies for the reduction of the fibril deposition of in-
sulin in commercial preparations.G, di-C7-PC and methylglyoxal (points) and fittings to equation
), ThT fluorescence intensity at 482 nm (AU) or ThT fluorescence
°C. B: experimental data of EGCG obtained at pH = 7.4 and T = 37°C.
Table 3 Parametric estimates and confidence intervals (α = 0.05) from the equation (1) applied to the aggregation
insulin increased data influenced by EGCG_1, EGCG_2, di-C7-PC and methylglyoxal concentrations
Parameters EGCG_1 EGCG_2 di-C7-PC Methylglyoxal
Aggregation model Xm (AU or %) 1.12±0.03 1.28±0.06 99.85±4.91 541.20±11.38
vm (AU h
−1 or % h−1) 0.18±0.01 0.25±0.04 1.55±0.27 219.68±20.98
λ (h) 4.78±0.28 53.34±0.28 124.62±5.86 2.92±0.12
Effect on Xm Kx 0.43±0.03 0.94±0.02 0.75±0.05 1.00±0.44
mx (mM) 0.68±0.08 0.01±0.00 0.65±0.12 1.80±1.25
ax 1.65±0.45 0.96±0.20 4.04±2.37 0.99±0.23
Effect on vm Kv NS NS 0.86±0.04 0.99±0.01
mv (mM) NS NS 0.47±0.06 0.42±0.07
av NS NS 2.51±2.35 0.74±0.08
Effect on λ Kλ 0.81±0.10 NS NS NS
mλ (mM) 0.50±0.08 NS NS NS
aλ 0.98±0.24 NS NS NS
EC50,τ (mM) 0.44 0.006 0.47 0.33
τ (h) 7.65 55.02 150.68 3.92
p-value <0.001 <0.001 <0.001 <0.001
Bf 0.88 0.80 1.00 1.04
Af 1.23 1.40 1.18 1.15
R2adj 0.992 0.977 0.984 0.974
Statistical values of adjusted coefficient of multiple determination (R2adj) and p-values from Fisher’s F-test (α = 0.05). Bf and Af are the bias and accuracy factor,
respectively. NS: non-significant.
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amyloid protein
The dependence of the kinetic parameters of fibril-
lation on the apigenin and taiwaniaflavone concen-
trations is represented in Figures 4A and B. Both
response surfaces were similar to that defined by the
simulation shown in Figure 2A. The three parameters
(vm, Xm, and λ) were clearly and significantly modified
by these chemical doses (Table 4), which show a longer
pre-nucleation phase, a lower elongation rate (post-nu-
cleation), and a lower elongation stage. Such responses
confirmed their chemical features of true inhibitors,
being the only case in which both kinetic parameters
(vm and λ) significantly affected aggregation process
[26]. All of the statistical tests corroborated the perfect
agreement between the experimental and the theoret-
ical data (e.g., R2adj > 0.99). The bias and accuracy fac-
tors (Bf and Af ) were also indicative of the good fitting
quality obtained with model (1).
The numerical values of EC50,τ confirmed the superior
antifibrillogenic capacity of the biflavonoid taiwaniafla-
vone (EC50,τ = 0.91 μM) compared with the monofla-
vonoid apigenin (EC50,τ = 2.45 μM). However, the time τ
was quite similar in both cases. This affirmation is con-
sistent with the conclusions reported in the original
work conducted by Thapa et al. [16].Inhibitory effect of osmolytes on Aβ42 amyloid protein
Different types of molecules have been recently sug-
gested as drug candidates for the treatment of neurode-
generative disorders caused by the anti-aggregation
properties of amyloid proteins [49]. One of the most inter-
esting candidates are osmolytes (compounds that protect
against the osmotic stress), such as the ectoines that are
obtained from aerobic heterotrophic bacteria [50]. The re-
sponse surface for hydroxyectoine (Figure 4C) shows a be-
havior that is similar to that obtained with the simulation
shown in Figure 2B. Based on the numerical fittings sum-
marized in Table 4, it was statistically demonstrated that
osmolytes inhibited the maximum aggregation rate and
the maximum fibrillation growth. In contrast, no signifi-
cant changes in the lag phase were observed. Therefore,
both osmolytes effectively blocked the post-nucleation
and the elongation stages but not the pre-nuclei forma-
tion. In addition, ectoine was much more effective as an
antineurotoxic (EC50,τ = 0.96 mM) than hydroxyectoine
(EC50,τ = 2.20 mM).
Inhibition of apomyoglobin fibrils formation by trehalose
The effect of trehalose on the apomyoglobin aggregation
kinetics was also studied using model (1), and excellent
statistical results were obtained from the modeling and
the description of the experimental data (Figure 4D and
Figure 4 Amyloid protein aggregation kinetics at different concentrations of apigenin, ectoine, taiwaniaflavone and trehalose (points)
and fittings to equation (1) (surface). X: aggregation data measured by ThT fluorescence intensity at 482 nm or 490 nm (AU). A: experimental
data of apigenin. B: taiwaniaflavone data. C: experimental data of hydroxyectoine. D: data of trehalose affecting apomyoglobin kinetics.
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nificantly inhibited the two kinetic parameters vm and
Xm without affecting the pre-nucleation phase (λ).
Nevertheless, its relative efficacy was obtained at a
much higher concentration (21.43 mM), and much
longer times (6.5 d) were required than compared with
the other cases studied.
Conclusions
In summary, a general bivariate model that combines
the logistic equation for the description of kinetics and
the Weibull equation for the chemical-concentration
response has been proposed for the characterization of
the inhibitory effects produced by several chemicals on
the growth of the aggregation of amyloid proteins. In
all cases, the inhibitory effects on the kinetic parame-
ters were established, and the theoretical response sur-
faces were in perfect agreement with the selected data.
In addition, the recent definition of true and apparentinhibitors reported by Martins [24] can be also evalu-
ated and validated. EGCG at pH 7.4 and a temperature
of 37°C was the best option for the reduction of the
formation of insulin fibrils (EC50,τ = 6 μM) but the
shortest time (τ) was obtained with methylglyoxal. For
the Aβ42 amyloid protein, the biflavonoid taiwaniafla-
vone produced the highest inhibition response at the
lowest dose (0.91 μM) and the shortest time (0.65 h).
The bivariate equation was validated using data obtained
by two methods based on different chemical phenomena.
Although this model can not define the mechanisms of ac-
tion of chemical inhibitors on protein aggregation, it pro-
vides a consistent tool for the comparison of the ability of
such compounds in the inhibition of the protein fibrilla-
tion process, regardless of the method used for its deter-
mination, and is a first step for the optimization of the
in vitro application of them. Further experiments and cor-
responding modeling should be done to establish its valid-
ity for in vivo applications of anti-aggregation chemicals.
Table 4 Parametric estimates and confidence intervals (α = 0.05) from the equation (1) applied to the aggregation of
Aβ42-amyloid protein increased data influenced by apigenin, ectoine, hidroxyectoine and taiwaniaflavone
concentrations
Parameters Apigenin Ectoine Hidroxyectoine Taiwaniaflavone Trehalose
Aggregation model Xm (AU) 17.43±0.50 (5.07±0.23) × 10
−3 (4.96±0.24) × 10−3 16.55±0.55 10.49±0.28
vm (AU h
−1 or AU d−1) 16.10±1.49 (0.24±0.05) × 10−3 (0.30±0.08) × 10−3 17.01±2.09 3.31±0.33
λ (h or d) 0.25±0.03 11.60±2.26 13.50±2.31 0.27±0.06 5.76±0.14
Effect on Xm Kx 0.41±0.06 1.00±0.99 1.00±0.90 0.78±0.05 0.44±0.03
mx (mM or μM) 6.52±1.93 11.82±11.03 66.70±65.78 2.32±0.38 51.58±7.27
ax 0.91±0.25 0.19±0.13 0.43±0.43 0.98±0.16 1.36±0.31
Effect on vm Kv 0.38±0.12 0.83±0.06 0.86±0.16 1.14±0.60 0.53±0.08
mv (mM or μM) 9.29±5.35 0.33±0.32 1.35 (NS) 1.88±1.73 33.22±17.26
av 1.35±1.13 0.36±0.14 0.34±0.20 0.40±0.21 0.66±0.33
Effect on λ Kλ 1.76±0.70 NS NS 1.27±1.13 NS
mλ (mM or μM) 2.16±0.29 NS NS 2.53±1.45 NS
aλ 2.39±0.99 NS NS 2.33±2.31 NS
EC50,τ (mM or μM) 2.45 0.96 2.20 0.91 21.43
τ (h or d) 0.75 17.31 20.52 0.65 6.54
p-value <0.001 <0.001 <0.001 <0.001 <0.001
Bf 0.99 1.04 1.00 1.02 1.03
Af 1.06 1.09 1.18 1.11 1.08
R2adj 0.995 0.988 0.984 0.990 0.995
The case of apomyoglobin affected by trehalose is also shown. Statistical values of adjusted coefficient of multiple determination (R2adj) and p-values from Fisher’s
F-test (α = 0.05). Bf and Af are the bias and accuracy factor, respectively. NS: non-significant.
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Reparameterization of logistic equation
It is well-known the autocatalytic origin of the logistic
equation based on the following differential equation:
dX
dt
¼ kappX 1− XXm
 
ðA:1Þ
which, integrated between X0→X and 0→t gives the ex-
plicit form of aggregation growth as a function of the
time:
X ¼ Xm
1þ exp ln Xm−X0X0
 	
−kappt
h i ðA:2Þ
The parameter τ is defined as the time required to obtain
the semimaximum fibrillation growth (when X =Xm/2):
Xm
2
¼ Xm
1þ Xm−X0X0
 	
exp −kappτ

 ⇒ τ ¼ 1kapp ln
Xm−X0
X0
 
ðA:3Þ
The inflection point (t = ti) can be obtained when the
second derivative from (A.1) is equal to zero and the
abscissa is isolated [31]:ti ¼ τ ¼ 1kapp ln
Xm−X0
X0
 
ðA:4Þ
The value of aggregation when t = ti is:
X tið Þ ¼ Xm2 ðA:5Þ
The slope in the inflection point (vm) is defined by the
following operation:
vm ¼ dXdt jt¼ti ¼
Xmkapp exp ln
Xm−X0
X0
 	
−kappti
h i
1þ exp ln Xm−X0X0
 	
−kappti
h ih i2
¼ Xmkapp
4
ðA:6Þ
The lag phase (λ) or pre-nucleation phase is defined as
the intersection of the tangent at the inflection point with
the abscissa (Figure 1):R ¼ X tið Þ þ vm L−tið Þ
with L = λ when R = 0:
    
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Xm
2vm
¼ τ− 2
kapp
ðA:7Þ
Reorganizing terms, two reparameterized functions can
be defined:
X ¼ Xm
1þ exp 2þ 4vmXm λ−tð Þ
h i ðA:8Þ
X ¼ Xm
1þ exp 4vmXm τ−tð Þ
h i ðA:9Þ
When parameters from both equations are influenced
by chemical agent concentration, they can be rewritten
as follows:
X ¼ Xm•
1þ exp 2þ 4vm•Xm• λ•−tð Þ
h i ðA:10Þ
X ¼ Xm•
1þ exp 4vm•Xm• τ•−tð Þ
h i ðA:11Þ
On the other hand, the calculation of the time τ for
EC50,τ is obtained by the following formula:
Xm•
4
¼ Xm•
1þ exp 4vm•Xm• τ•−τð Þ
h i⇒τ
¼ τ•−Xm• ln34vm• ðA:12Þ
Weibull equation and bivariate model (1)
The most interesting form of Weibull equation for
dose-response modelling is expressed as follows [35]:
C
 a  Y ¼ Ym 1− exp − ln2 m ðA:13Þ
where, Y is the response and Ym the maximum re-
sponse, m is the concentration corresponding to the
semi-maximum response, C is the concentration and a
is a shape parameter related to the maximum slope of
the response.
This equation can be modified according with the
graphical tendencies of chemicals effects (Figure 1) on
the aggregation parameters [38]:
θ ¼ θ0 1−Y θð Þ or θ ¼ θ0 1þ Y θð Þ ðA:14Þ
Thus, decrease of vm and Xm and increase of λ and τ
were the characteristic responses observed for the inhib-
ition of amyloid protein fibrillation kinetics induced by
chemicals:Xm• ¼ Xm 1−Kx 1− exp − ln2 Cmx
ax
vm• ¼ vm 1−Kv 1− exp − ln2 Cmv
 av   
λ• ¼ λ 1þ K λ 1− exp − ln2 Cmλ
 aλ   
τ• ¼ τ 1þ K τ 1− exp − ln2 Cmτ
 aτ   
ðA:15Þ
When the equations (A.15) are inserting directly on
equation (A.10) or (A.11), the bivariate model (1) is obtained.
Additional file
Additional file 1: Excel spreadsheet used for modeling the
Ab42amyloid apigenin case.
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